To the editor:
Rearrangement of NOTCH1 or BCL3 can independently trigger progression of CLL
Recent data indicate that NOTCH1 mutations significantly increase the risk of CLL progression toward Richter syndrome (RS) and chemoresistance, 1, 2 and that activation of NOTCH1 at time of CLL diagnosis is an independent prognostic factor of poor survival. 1, 3 We report here a case of CLL with a novel rearrangement of NOTCH1 identified at the time of RS. The patient, a 58-year-old male, was diagnosed with CLL (unmutated VH) in RS in June 2003. Cytogenetic analysis and FISH on peripheral blood (PBL), bone marrow (BM), and lymph node (LN) cells showed 2 related clones: one with an isolated ϩ12 and a second with ϩ12 and dic(9;14)(q34;q32) (supplemental Table 1 , available on the Blood Web site; see the Supplemental Materials link at the top of the online article). FISH analysis of dic(9;14)(q34;q32) indicated that this aberration resulted in juxtaposition of 3ЈIGH and 5ЈNOTCH1, as evidenced by the loss of sequences telomeric to the breakpoints ( Figure 1A-D) . These imbalances were confirmed by array CGH (data not shown). The targeting of NOTCH1 by dic(9;14) was evidenced by qRT-PCR analysis, which showed a 10-fold upregulation of NOTCH1 mRNA ( Figure 1E ) and a low expression of the neighboring genes (GPSM11, CARD9, DNL2). Immunoblotting of a cell lysate from LN with a NOTCH1 antibody recognizing active, cleaved NOTCH1 (Val1744) identified a band corresponding to activated intracellular NOTCH1 ( Figure 1F ), suggesting an additional truncating mutation. Indeed, sequence analysis identified a 2 basepair deletion, ⌬CT7544-7545/P2515fs, in the nucleotide sequence encoding the PEST domain ( Figure 1G ). This mutation resulting in expression of a truncated intracellular NOTCH1 allele is recurrent in T-ALL 4 and CLL. [1] [2] [3] 5 The patient was treated and achieved complete remission (supplemental Table 1 ). In 2007, however, CLL relapsed and an examination of BM identified a clone with a sole ϩ12 negative for ⌬CT7544-7545/P2515fs. Two years later, CLL progressed and BM revealed an evolved clone with complex aberrations including ϩ12 and t(14;19)(q32;q13)/IGH-BCL3 but lacking dic(9;14)(q34;q32). Of note, BM was again positive for ⌬CT7544-7545/P2515fs. Despite treatment, 2 clones harboring ϩ12, one with t(14;19) and a second with new additional karyotypic changes, were seen in the analyzed BM (06/2011) positive for ⌬CT7544-7545/P2515fs. TP53 disruption frequently associated with RS 6 was not observed in the analyzed Table 1 ). Four months later, the patient developed peripheral T-cell lymphoma, a rare recurrent event in CLL. 7 Altogether, the present case allows us to deduce the sequence of multiple genetic defects driving development and progression of CLL. An initial clone with ϩ12, likely present at a presymptomatic CLL phase, later acquired an activating mutation of NOTCH1. Subsequent acquisition of dic(9;14)/IGH-NOTCH1 triggered Richter transformation. After a few years, a persistent, chemorefractory NOTCH1-mutated clone underwent another hit, t(14;19)/IGH-BCL3, which initiated the second progression that was followed by a fatal CLL-unrelated T-cell lymphoma. Our findings confirm the risk of activating mutations of NOTCH1 in Richter transformation of CLL, 1,2 particularly CLL with ϩ12, 3 and highlight that a residual chemotherapy- 
